港股異動 | 中國生物製藥(1177.HK)漲4.5% 獲多家券商看好
格隆匯9月2日丨中國生物製藥(1177.HK)現報9.29港元,漲幅4.5%,最新總市值1753.27億港元。第一上海證券指,考慮到集採風險充分釋放及公司將於明年進入新品密集收穫期,公司有望進入新的快速發展階段,我們調整盈利預測,提升目標價至11.00港元(已考慮發行紅股),對應2021年每股盈利的45倍市盈率,維持買入評級。國信證券指,隨着新品種的上市放量和疫情影響的逐步消除,公司下半年業績增速將進一步提升,明年起增速將回升至20%以上。預計2020-22年的淨利潤為31.6/38.2/47.1億元,同比增長17%/21%/23%,維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.